Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organelles such as the vacuole make important contributions to tolerance and/or trailing growth.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“In Saccharomyces cerevisiae several genes involved in retrograde trafficking modulate tolerance and/or trailing growth, including VPS2127,51, VPS15 and VPS5194; Rim101 may influence tolerance via its ability to regulate the transcription of key components of the vacuolar trafficking pathway95.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“Despite extensive efforts, target-based cell-free screening of synthetic chemical libraries has failed to deliver any new classes of antifungals or antibacterials in clinical practice (Payne et al., 2007; Roemer and Krysan, 2014).”
From A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance (2016) · cites this paper as Roemer and Krysan, 2014
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Functional profiling of the Saccharomyces cerevisiae genome
Giaever, G., Chu, A. M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. (2002) · Nature · doi:10.1038/nature00935 · Cited by 4,316
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.141 · Cited by 1,041
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
Tackling Human Fungal Infections
Brown, G. D., Denning, D. W., & Levitz, S. M. (2012) · Science · doi:10.1126/science.1222236 · Cited by 619
Amphotericin primarily kills yeast by simply binding ergosterol
Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117280109 · Cited by 608 · cited 1×
“Amphotericin B binds to ergosterol, a membrane sterol that is unique to fungi, as part of its mechanism of action (Gray et al. 2012).”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Genomic profiling of drug sensitivities via induced haploinsufficiency
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., & Davis, R. W. (1999) · Nature Genetics · doi:10.1038/6791 · Cited by 570
Shoemaker, D. D., Lashkari, D. A., Morris, D., Mittmann, M., & Davis, R. W. (1996) · Nature Genetics · doi:10.1038/ng1296-450 · Cited by 569
Combination Antifungal Therapy for Cryptococcal Meningitis
Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 545
Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy
Ejim, L., Farha, M. A., Falconer, S. B., Wildenhain, J., Coombes, B. K., Tyers, M., Brown, E. D., & Wright, G. D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.559 · Cited by 525
Changing patterns and trends in systemic fungal infections
Richardson, M. D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki218 · Cited by 525
Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 504
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 2×
“fumigatus, and that it is observed in an invertebrate model of candidiasis (Cowen et al. 2009; Singh et al. 2009; Shapiro et al. 2011).”
BackgroundSerologic Evidence for Cryptococcus neoformans Infection in Early Childhood
Goldman, D. L., Khine, H., Abadi, J., Lindenberg, D. J., Pirofski, L.-A., Niang, R., & Casadevall, A. (2001) · Pediatrics · doi:10.1542/peds.107.5.e66 · Cited by 413
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 2×
“fumigatus, and that it is observed in an invertebrate model of candidiasis (Cowen et al. 2009; Singh et al. 2009; Shapiro et al. 2011).”
BackgroundClinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry
Steinbach, W. J., Marr, K. A., Anaissie, E. J., Azie, N., Quan, S.-P., Meier-Kriesche, H.-U., Apewokin, S., & Horn, D. L. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.08.003 · Cited by 353
Discovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J., Meinz, M., Thompson, J., Curotto, J., Dreikorn, S., Rosenbach, M., Douglas, C., Abruzzo, G., Flattery, A., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 326
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303 · cited 3×
“, Aspergillus) leads to a poor correlation between organism growth and optical density (Bowman et al. 2002).”
BackgroundInfluentialThe ‘obligate diploid’ Candida albicans forms mating-competent haploids
Hickman, M. A., Zeng, G., Forche, A., Hirakawa, M. P., Abbey, D., Harrison, B. D., Wang, Y.-M., Su, C.-H., Bennett, R. J., Wang, Y., et al. (2013) · Nature · doi:10.1038/nature11865 · Cited by 284
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans
Xu, D., Jiang, B., Ketela, T., Lemieux, S., Veillette, K., Martel, N., Davison, J., Sillaots, S., Trosok, S., Bachewich, C., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030092 · Cited by 254
Self-citationBicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604716 · Cited by 227
Mucormycosis in Organ and Stem Cell Transplant Recipients
Lanternier, F., Sun, H.-Y., Ribaud, P., Singh, N., Kontoyiannis, D. P., & Lortholary, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis195 · Cited by 212
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Antifungal Drug Discovery: Something Old and Something New
Butts, A., & Krysan, D. J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002870 · Cited by 182
Self-citationBad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Pruett, T. (2010) · Yearbook of Surgery · doi:10.1016/s0090-3671(10)79814-1 · Cited by 176
Lesage, G., Sdicu, A.-M., Ménard, P., Shapiro, J., Hussein, S., & Bussey, H. (2004) · Genetics · doi:10.1534/genetics.167.1.35 · Cited by 166
Pfaller, M. A., & Barry, A. L. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.8.1992-1996.1994 · Cited by 160
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Self-citationHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Confronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147
Self-citationMonteiro, M. C., de la Cruz, M., Cantizani, J., Moreno, C., Tormo, J. R., Mellado, E., De Lucas, J. R., Asensio, F., Valiante, V., Brakhage, A. A., et al. (2012) · SLAS Discovery · doi:10.1177/1087057111433459 · Cited by 144
Discovery of Wall Teichoic Acid Inhibitors as Potential Anti-MRSA β-Lactam Combination Agents
Wang, H., Gill, C., Lee, S. H., Mann, P. A., Zuck, P. D., Meredith, T. C., Murgolo, N., She, X., Kales, S., Liang, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.11.013 · Cited by 136
Self-citationTsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 135
Bugs, drugs and chemical genomics
Roemer, T., DAVIES, J. E., Giaever, G. N., & Nislow, C. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.744 · Cited by 127
Self-citationSeiradake, E., Mao, W., Hernandez, V. S., Baker, S. J., Plattner, J. J., Alley, M. R. K., & Cusack, S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.073 · Cited by 118
McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks466 · Cited by 100
Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00345-07 · Cited by 100
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
The challenge of managing fusariosis
Muhammed, M., Carneiro, H. A., Coleman, J. J., & Mylonakis, E. E. (2011) · Virulence · doi:10.4161/viru.2.2.15015 · Cited by 94
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
Lewis, R. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 92
Jiang, B., Xu, D., Allocco, J., Parish, C. A., Davison, J., Veillette, K., Sillaots, S., Hu, W., Rodriguez-Suarez, R. J., Trosok, S., et al. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.016 · Cited by 85
Self-citationDiscovery of a Novel Class of Orally Active Antifungal β-1,3- d -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75
Rex, J. H., Walsh, T. J., Nettleman, M. D., Anaissie, E. J., Bennett, J. E., Bow, E. J., Carillo‐Munoz, A. J., Chavanet, P., Cloud, G. A., Denning, D. W., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/320876 · Cited by 74
Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis
Luo, G., Gebremariam, T., Lee, H.-K., French, S. W., Wiederhold, N. P., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-13 · Cited by 73
Mann, P. A., Müller, A., Xiao, L., Pereira, P. M., Yang, C., Lee, S. H., Wang, H., Trzeciak, J., Schneeweis, J. E., dos Santos, M. M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400487f · Cited by 69
Self-citationDiscovery of a Small-Molecule Inhibitor of β-1,6-Glucan Synthesis
Kitamura, A., Someya, K., Hata, M., Nakajima, R., & Takemura, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00844-08 · Cited by 64
Genetic Susceptibility to Fungal Infections in Humans
Lionakis, M. S. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0076-4 · Cited by 62
LaFleur, M. D., Lucumi, E., Napper, A. D., Diamond, S. L., & Lewis, K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq530 · Cited by 59
Bills, G. F., Platas, G., Overy, D. P., Collado, J., Fillola, A., Jiménez, M. R., Martı́n, J., del Val, A. G., Vicente, F., Tormo, J. R., et al. (2009) · Mycologia · doi:10.3852/08-163 · Cited by 56
Self-citationTreatment of cryptococcal meningitis in resource limited settings
Sloan, D. J., Dedicoat, M. J., & Lalloo, D. G. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832fa214 · Cited by 55
Echinocandins: Are They All The Same?
Mukherjee, P. K., Sheehan, D. F., Puzniak, L., Schlamm, H. T., & Ghannoum, M. A. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.6.319 · Cited by 51
High-Throughput Nano-Biofilm Microarray for Antifungal Drug Discovery
Srinivasan, A., Leung, K. P., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · mBio · doi:10.1128/mbio.00331-13 · Cited by 45
Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis
Bratton, E. W., Husseini, N. E., Chastain, C. A., Lee, M. S., Poole, C., Stürmer, T., Weber, D. J., Juliano, J. J., & Perfect, J. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01800-12 · Cited by 44
Kitamura, A., Higuchi, S., Hata, M., Kawakami, K., Yoshida, K., Namba, K., & Nakajima, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00435-09 · Cited by 41
Xu, D., Ondeyka, J. G., Harris, G. H., Zink, D. L., Kahn, J. N., Wang, H., Bills, G. F., Platas, G., Wang, W., Szewczak, A. A., et al. (2011) · Journal of Natural Products · doi:10.1021/np2001573 · Cited by 40
Self-citationHeasley, B. H., Pacofsky, G. J., Mamai, A., Liu, H., Nelson, K., Coti, G., Peel, M. R., Balkovec, J. M., Greenlee, M. L., Liberator, P., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.031 · Cited by 35
Combinatory effect of fluconazole and FDA-approved drugs against Candida albicans
Kaneko, Y., Fukazawa, H., Ohno, H., & Miyazaki, Y. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0639-0 · Cited by 35
VORICONAZOLE VERSUS AMPHOTERICIN B FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200205000-00033 · Cited by 35
A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans
Rabjohns, J. L. A., Park, Y.-D., Dehdashti, J., Sun, W., Henderson, C., Zelazny, A., Metallo, S. J., Zheng, W., & Williamson, P. R. (2014) · SLAS Discovery · doi:10.1177/1087057113496847 · Cited by 33
A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis
DiDone, L., Scrimale, T., Baxter, B. K., & Krysan, D. J. (2010) · Nature Protocols · doi:10.1038/nprot.2010.47 · Cited by 22
Self-citationOvercoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles
Youngsaye, W., Dockendorff, C., Vincent, B., Hartland, C. L., Bittker, J. A., Dandapani, S., Palmer, M. A. J., Whitesell, L. J., Lindquist, S. L., Schreiber, S. L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.035 · Cited by 20
Combination Therapy for Cryptococcal Meningitis
Baddour, L. M. (2013) · Journal watch · doi:10.1056/id201304030000002 · Cited by 7
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Self-citationPathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Anti-Fungal Efficacy and Mechanisms of Flavonoids
Al Aboody, M. S., & Mickymaray, S. (2020) · Antibiotics · doi:10.3390/antibiotics9020045 · Cited by 472
Metadata
- Authors
- Roemer, T., & Krysan, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Rochester Medicine (US)
- ORCID
- Krysan, D. J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-05-01
- Volume
- 4
- Issue
- 5
- Pages
- a019703-a019703
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3996373
- OpenAlex
- W2134122507
- Cited by
- 593
- References
- 78
- Citations by year
- 2026: 39 · 2025: 56 · 2024: 69 · 2023: 51 · 2022: 58 · 2021: 68 · 2020: 71 · 2019: 42 · 2018: 50 · 2017: 38 · 2016: 30 · 2015: 18 · 2014: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Rochester
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI097142, R01AI091422)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal drug development, invasive fungal infections, antifungal drug discovery, unmet clinical needs, immunocompromised patients
- MeSH terms
- Antifungal Agents, Forecasting, Humans, Mycoses, Technology, Pharmaceutical, Treatment Outcome, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.